Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Abstract Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings. Identifying combination treatments to sensitize tumor cells and/or overcome resistance to olaparib is critical. Polo-like...

Full description

Bibliographic Details
Published in:	Cell Death and Disease
Main Authors:	Michela Chiappa, Alessandra Decio, Luca Guarrera, Ilaria Mengoli, Anju Karki, Divora Yemane, Carmen Ghilardi, Eugenio Scanziani, Simone Canesi, Maria C. Barbera, Ilaria Craparotta, Marco Bolis, Robert Fruscio, Chiara Grasselli, Tommaso Ceruti, Massimo Zucchetti, Jesse C. Patterson, Robin A. Lu, Micheal B. Yaffe, Maya Ridinger, Giovanna Damia, Federica Guffanti
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-07-01
Online Access:	https://doi.org/10.1038/s41419-024-06894-1

Similar Items

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
by: Roberta Affatato, et al.
Published: (2022-05-01)

BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models
by: Federica Guffanti, et al.
Published: (2024-06-01)

Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
by: Federica Guffanti, et al.
Published: (2024-08-01)

Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer
by: Nikita Sinha, et al.
Published: (2025-03-01)

Targeting the DNA damage response in cancer
by: Guffanti Federica, et al.
Published: (2024-11-01)

Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice
by: Tommaso Ceruti, et al.
Published: (2023-12-01)

Antioxidant and Antisteatotic Activities of Fucoidan Fractions from Marine and Terrestrial Sources
by: Zeinab El Rashed, et al.
Published: (2021-07-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)

Antioxidant and Antisteatotic Activities of a New Fucoidan Extracted from <i>Ferula hermonis</i> Roots Harvested on Lebanese Mountains
by: Zeinab El Rashed, et al.
Published: (2021-02-01)

Cutaneous vasculitis as a side effect of olaparib
by: Paula Andrea Ramos Chaparro, MD, et al.
Published: (2025-10-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line
by: Mehmet Kadir Erdogan, et al.
Published: (2025-02-01)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
by: Rachel Dunn, et al.
Published: (2021-01-01)

NLRP4 drives olaparib resistance in pancreatic cancer
by: Mingming Xiao, et al.
Published: (2024-12-01)

Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model
by: Danuta Szkutnik-Fiedler, et al.
Published: (2024-12-01)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
by: Yize Mao, et al.
Published: (2018-04-01)

Improving olaparib exposure to optimize adverse effects management
by: Marylise Sterlé, et al.
Published: (2024-04-01)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
by: Abigale Clark, DO, et al.
Published: (2023-09-01)

An in vitro model of drug-resistant seizures for selecting clinically effective antiseizure medications in Febrile Infection-Related Epilepsy Syndrome
by: Milica Cerovic, et al.
Published: (2023-03-01)

A Quaternary Solid Dispersion System for Improving the Solubility of Olaparib
by: Tae-Han Yun, et al.
Published: (2025-01-01)

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer
by: Hiroaki Ishida, et al.
Published: (2025-02-01)

Clinical and radiological pattern of olaparib-induced interstitial lung disease
by: Alexandre Brudon, et al.
Published: (2024-09-01)

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib
by: Tao Zhang, et al.
Published: (2024-02-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Synergistic mechanism of olaparib and cisplatin on breast cancer elucidated by network pharmacology
by: Qiang Niu, et al.
Published: (2025-04-01)

Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
by: Dong R, et al.
Published: (2024-12-01)

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
by: Xin‐Yuan Lei, et al.
Published: (2024-12-01)

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
by: Christoph Rogmans, et al.
Published: (2024-11-01)

Investigation of Stabilized Amorphous Solid Dispersions to Improve Oral Olaparib Absorption
by: Taehan Yun, et al.
Published: (2024-07-01)

Olaparib Process Development Employing Quality by Design (QbD) Principles
by: Amarendhar Manda, et al.
Published: (2024-07-01)

Counting the cost of public and philanthropic R&D funding: the case of olaparib
by: L. Schmidt, et al.
Published: (2022-12-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01)

Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer
by: Danny Lavigne, MD, et al.
Published: (2024-07-01)

Promising Response of Olaparib in Patient With Germline -Mutated Metastatic Gastric Cancer
by: Kok Hoe Chan MD, et al.
Published: (2024-03-01)

Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
by: Yuanyuan Yang, et al.
Published: (2023-12-01)

Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells
by: Benigno C. Valdez, et al.
Published: (2023-11-01)

Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study
by: Hamid Sheikh, et al.
Published: (2023-05-01)

Intentions versus Outcomes: Cooperation and Fairness in a Sequential Prisoner’s Dilemma with Nature
by: Garret Ridinger
Published: (2021-07-01)

Shame and Theory-of-Mind Predicts Rule-Following Behavior
by: Garret Ridinger
Published: (2020-09-01)